What is William Blair's Forecast for NBIX FY2025 Earnings?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at William Blair dropped their FY2025 earnings per share estimates for Neurocrine Biosciences in a research note issued to investors on Tuesday, May 6th. William Blair analyst M. Minter now anticipates that the company will earn $3.71 per share for the year, down from their previous forecast of $3.87. William Blair has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The company had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period last year, the business posted $1.20 earnings per share.

Several other brokerages have also recently weighed in on NBIX. UBS Group increased their price target on shares of Neurocrine Biosciences from $137.00 to $152.00 and gave the company a "buy" rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft began coverage on Neurocrine Biosciences in a report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective for the company. Guggenheim upped their target price on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a report on Tuesday. HC Wainwright reduced their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Finally, Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $162.00.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $121.54 on Thursday. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The company has a market capitalization of $12.02 billion, a P/E ratio of 36.94, a PEG ratio of 0.77 and a beta of 0.26. The stock has a 50 day moving average price of $106.12 and a two-hundred day moving average price of $121.80.

Neurocrine Biosciences announced that its Board of Directors has authorized a stock buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the sale, the director now directly owns 37,491 shares of the company's stock, valued at $4,131,508.20. The trade was a 44.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kyle Gano sold 980 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $118.39, for a total transaction of $116,022.20. Following the sale, the chief executive officer now directly owns 137,658 shares of the company's stock, valued at $16,297,330.62. This represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,907 shares of company stock worth $4,935,982 in the last quarter. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the business. Golden State Wealth Management LLC bought a new position in Neurocrine Biosciences in the fourth quarter worth approximately $25,000. Huntington National Bank lifted its stake in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after purchasing an additional 97 shares during the last quarter. Brooklyn Investment Group grew its stake in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new position in Neurocrine Biosciences in the first quarter worth about $34,000. Finally, GeoWealth Management LLC lifted its position in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after buying an additional 102 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.